Alpha Teknova (NASDAQ:TKNO) & Charles River Laboratories International (NYSE:CRL) Head-To-Head Review

Charles River Laboratories International (NYSE:CRL) and Alpha Teknova (NASDAQ:TKNO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Insider and Institutional Ownership

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Charles River Laboratories International has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Valuation & Earnings

This table compares Charles River Laboratories International and Alpha Teknova”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02 billion	4.16	-$144.34 million	$0.91	383.10
Alpha Teknova	$40.52 million	13.69	-$17.26 million	($0.29)	-30.41

Alpha Teknova has lower revenue, but higher earnings than Charles River Laboratories International. Alpha Teknova is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Charles River Laboratories International and Alpha Teknova, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1	3	13	0	2.71
Alpha Teknova	1	1	4	0	2.50

Charles River Laboratories International currently has a consensus price target of $308.17, suggesting a potential downside of 11.60%. Alpha Teknova has a consensus price target of $8.75, suggesting a potential downside of 0.79%. Given Alpha Teknova’s higher possible upside, analysts plainly believe Alpha Teknova is more favorable than Charles River Laboratories International.

Profitability

This table compares Charles River Laboratories International and Alpha Teknova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	1.01%	16.95%	6.93%
Alpha Teknova	-34.76%	-24.95%	-16.27%

Summary

Charles River Laboratories International beats Alpha Teknova on 10 of the 14 factors compared between the two stocks.

About Charles River Laboratories International

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

About Alpha Teknova

Alpha Teknova, Inc. is a life sciences company that develops and manufactures critical reagents and other products used in biomedical research, biopharmaceutical development and advanced therapies. The company provides laboratory and production materials designed to support applications including cell and gene therapy, molecular diagnostics, next-generation sequencing, vaccine development and pharmaceutical manufacturing. Its offerings include research-use-only and current Good Manufacturing Practice (cGMP) reagents, buffers, media and other custom-formulated solutions.